Optimi Health’s goal is to bring an evolving product family of functional mushroom-based formulations to the market to transform and “optimize” human development in the field of physical, spiritual and mental well-being.
Optimi Health
Optimi Health is developing a vertically integrated industrial-scale operation, including supplements, nutraceuticals and future pharmaceutical opportunities, focusing on the fast-growing functional mushroom sector.
Their manufacturing facility Optimi Farms is designed to accommodate either functional mushroom or pharmaceutical grade production (GMP) of functional or psychoactive mushrooms i.e psilocybin. The company has received a Research Exemption with Health Canada to explore psychoactive mushrooms.
In September 2020, Optimi raised $4,490,751.25 in an oversubscribed non-brokered private placement. At IPO in February 2021, the company raised $16.56 million.
“All-natural human optimization starts here”
News
- Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application (Globe Newswire, October 2021)
Activities
B2B
B2C
Manufacturing
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility (GlobeNewswire, 28 April 2022)Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health (GlobeNewswire, 31 May 2022)